Literature DB >> 20660029

Tumor-induced hypophosphatemic rickets in an adolescent boy--clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue.

G Haeusler1, M Freilinger, M Dominkus, M Egerbacher, G Amann, A Kolb, W Schlegel, A Raimann, A Staudenherz.   

Abstract

CONTEXT: The mechanism behind disabling muscle weakness in tumor-induced hypophosphatemic rickets is obscure. Histological investigation of growth plate tissue of patients with tumor-induced osteomalacia has so far not been reported. PATIENT: A mesenchymal tumor was detected in the left distal fibula by (68)Ga-DOTATOC in a 17-yr-old boy with adolescent onset of severe hypophosphatemic rickets. Disabling muscle weakness improved within days after surgery, and normal mobility was restored within months. METHODS AND
RESULTS: The resected tissue included part of the growth plate allowing immunohistochemical investigation. Positive staining of FGF23 was found in the tumor cells and in hypertrophic chondrocytes, osteoblasts, and osteoclasts of the adjacent growth plate. This distribution matched that found in growth plate tissue of a healthy control. We found positive staining for the somatostatin receptor not only in the tumor but also within the growth plate and adjacent bony tissue in the patient and the healthy control. Muscle tissue provided evidence for a partial defect in respiratory chain complexes I-IV. Biochemical markers were nearly or completely restored to normal 12 months after surgery.
CONCLUSIONS: Hypertrophic growth plate chondrocytes are a target or source of FGF23 in tumor-induced osteomalacia. Low serum phosphate, FGF23, or other factors produced by the tumor may interfere with mitochondrial function.

Entities:  

Mesh:

Year:  2010        PMID: 20660029     DOI: 10.1210/jc.2010-0543

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 2.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

3.  Tumor-induced osteomalacia: experience from a South American academic center.

Authors:  G González; R Baudrand; M F Sepúlveda; N Vucetich; F J Guarda; P Villanueva; O Contreras; A Villa; F Salech; L Toro; L Michea; P Florenzano
Journal:  Osteoporos Int       Date:  2017-03-25       Impact factor: 4.507

4.  Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.

Authors:  Marie Paquet; Mathieu Gauthé; Jules Zhang Yin; Valérie Nataf; Ophélie Bélissant; Philippe Orcel; Christian Roux; Jean-Noël Talbot; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-12       Impact factor: 9.236

5.  68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia.

Authors:  Diala El-Maouche; Samira M Sadowski; Georgios Z Papadakis; Lori Guthrie; Candice Cottle-Delisle; Roxanne Merkel; Corina Millo; Clara C Chen; Electron Kebebew; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

6.  Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management.

Authors:  Deepa Singh; Aditi Chopra; Mudalsha Ravina; Srikant Kongara; Eesh Bhatia; Narvesh Kumar; Sushil Gupta; Subhash Yadav; Preeti Dabadghao; Rajnikant Yadav; Veeresh Dube; Utham Kumar; Manish Dixit; Sanjay Gambhir
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

Review 7.  Hypophosphatemic rickets due to perturbations in renal tubular function.

Authors:  Maria Goretti M G Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714

8.  Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin.

Authors:  Anke H Hautmann; Josef Schroeder; Peter Wild; Matthias G Hautmann; Elisabeth Huber; Patrick Hoffstetter; Martin Fleck; Christiane Girlich
Journal:  Case Rep Endocrinol       Date:  2014-08-24

Review 9.  Tumour-induced osteomalacia: a literature review and a case report.

Authors:  Jolanta Dadoniene; Marius Miglinas; Dalia Miltiniene; Donatas Vajauskas; Dmitrij Seinin; Petras Butenas; Tomas Kacergius
Journal:  World J Surg Oncol       Date:  2016-01-08       Impact factor: 2.754

10.  A case report of phosphaturic mesenchymal tumor-induced osteomalacia.

Authors:  Weiqian Wu; Chongyang Wang; Jianwei Ruan; Feng Chen; Ningjun Li; Fanghu Chen
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.